This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khanna, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khanna, N.

 Previous Article  |  Next Article 

Journal of Virology, May 2009, p. 4404-4411, Vol. 83, No. 9
0022-538X/09/$08.00+0     doi:10.1128/JVI.02657-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

JC Virus-Specific Immune Responses in Human Immunodeficiency Virus Type 1 Patients with Progressive Multifocal Leukoencephalopathy{triangledown}

Nina Khanna,1,2 Marcel Wolbers,3 Nicolas J. Mueller,4 Christian Garzoni,5 Renaud A. Du Pasquier,6 Christoph A. Fux,7 Pietro Vernazza,8 Enos Bernasconi,9 Raphael Viscidi,10 Manuel Battegay,1 Hans H. Hirsch,1,2* for the Swiss HIV Cohort Study

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, CH-4031 Basel, Switzerland,1 Institute for Medical Microbiology, Department of Biomedicine, University of Basel, CH-4003 Basel, Switzerland,2 Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, CH-4031 Basel, Switzerland,3 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH-8091 Zurich, Switzerland,4 Division of Infectious Diseases and Laboratory of Virology, University Hospital Geneva, CH-1205 Geneva, Switzerland,5 Divisions of Neurology and Immunology, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland,6 Division of Infectious Diseases, University Hospital and University of Bern, CH-3010 Bern, Switzerland,7 Department of Internal Medicine, Cantonal Hospital, CH-9000 St. Gallen, Switzerland,8 Department of Internal Medicine, Regional Hospital, CH-6900 Lugano, Switzerland,9 Stanley Division of Developmental Neurovirology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland,10

Received 24 December 2008/ Accepted 2 February 2009

Progressive multifocal leukoencephalopathy (PML) is a frequently fatal disease caused by uncontrolled polyomavirus JC (JCV) in severely immunodeficient patients. We investigated the JCV-specific cellular and humoral immunity in the Swiss HIV Cohort Study. We identified PML cases (n = 29), as well as three matched controls per case (n = 87), with prospectively cryopreserved peripheral blood mononuclear cells and plasma at diagnosis. Nested controls were matched according to age, gender, CD4+ T-cell count, and decline. Survivors (n = 18) were defined as being alive for >1 year after diagnosis. Using gamma interferon enzyme-linked immunospot assays, we found that JCV-specific T-cell responses were lower in nonsurvivors than in their matched controls (P = 0.08), which was highly significant for laboratory- and histologically confirmed PML cases (P = 0.004). No difference was found between PML survivors and controls or for cytomegalovirus-specific T-cell responses. PML survivors showed significant increases in JCV-specific T cells (P = 0.04) and immunoglobulin G (IgG) responses (P = 0.005). IgG responses in survivors were positively correlated with CD4+ T-cell counts (P = 0.049) and negatively with human immunodeficiency virus RNA loads (P = 0.03). We conclude that PML nonsurvivors had selectively impaired JCV-specific T-cell responses compared to CD4+ T-cell-matched controls and failed to mount JCV-specific antibody responses. JCV-specific T-cell and IgG responses may serve as prognostic markers for patients at risk.


* Corresponding author. Mailing address: Institute for Medical Microbiology, Department of Biomedicine, University of Basel, Petersplatz 10, CH-4003 Basel, Switzerland. Phone: 41 61 267-3262. Fax: 41 61 267-3283. E-mail: Hans.Hirsch{at}unibas.ch

{triangledown} Published ahead of print on 11 February 2009.


Journal of Virology, May 2009, p. 4404-4411, Vol. 83, No. 9
0022-538X/09/$08.00+0     doi:10.1128/JVI.02657-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Korman, B. D., Tyler, K. L., Korman, N. J. (2009). Progressive Multifocal Leukoencephalopathy, Efalizumab, and Immunosuppression: A Cautionary Tale for Dermatologists. Arch Dermatol 145: 937-942 [Full Text]